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ABSTRACT 53 
Context. Lower Anogenital Squamous Terminology (LAST) standardization recommended 54 
p16INK4a immunohistochemistry (p16 IHC) on biopsies diagnosed morphologically as cervical 55 
intraepithelial neoplasia (CIN) grade 2 (CIN2) to classify them as low-grade or high-grade 56 
squamous intraepithelial lesions (HSIL). 57 
Objective. To describe the relationships of p16 IHC and other biomarkers associated with 58 
cervical-cancer risk with biopsies diagnoses. 59 
Design. A state-wide, stratified sample of cervical biopsies diagnosed by the community 60 
pathologists (CP), including 1,512 CIN2, underwent a consensus, expert pathologists panel (EP) 61 
review (without p16 IHC results), p16 IHC interpreted by a third pathology group, and HPV 62 
genotyping, results of which were grouped hierarchically according to cancer risk. Antecedent 63 
cytologic interpretations were also available. 64 
Results. Biopsies were more likely to test p16 IHC positive with increasing severity of CP 65 
diagnoses, overall (Ptrend<.001) and within each HPV risk group (Ptrend≤.001). All abnormal 66 
grades of CP-diagnosed biopsies were more likely to test p16 IHC positive with a higher HPV 67 
risk group (Ptrend<.001), and testing p16 IHC positive was associated with higher HPV risk group 68 
than testing p16 IHC negative for each grade of CP-diagnosed biopsies (P<.001). p16 IHC-69 
positive, CP-diagnosed CIN2 biopsies were less likely than CP-diagnosed CIN3 biopsies to test 70 
HPV16 positive, have an antecedent HSIL+ cytology, or to be diagnosed as CIN3+ by the EP 71 
(P<.001 for all). p16 IHC-positive, CP-diagnosed CIN1 biopsies had lower HPV risk groups 72 
than p16 IHC-negative, CP-diagnosed CIN2 biopsies (P<.001). 73 
Conclusions. p16 IHC-positive, CP-diagnosed CIN2 appears to be lower cancer risk than CP-74 
diagnosed CIN3. LAST classification of “HSIL” diagnosis, which includes p16 IHC-positive 75 
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CIN2, should annotate the morphologic diagnosis (CIN2 or CIN3) to inform all management 76 
decisions, which is especially important for young (<30 years) women diagnosed with CIN2 for 77 
whom surveillance rather than treatment is recommended.  78 
5 
 
INTRODUCTION 79 
Persistent cervical infections by 12-15 high-risk human papillomavirus (HPV) genotypes 80 
cause nearly all cervical cancers1 and most of the immediate precursor cervical abnormalities, 81 
including cervical intraepithelial neoplasia (CIN) grade 2 (CIN2), grade 3 (CIN3), and 82 
adenocarcinoma in situ (AIS). HPV16 and HPV18 are the most carcinogenic HPV genotypes, 83 
with HPV16 causing approximately 50-60% of cervical cancers and HPV18 causing 10-15% of 84 
cervical cancers.2 The other 10-13 HPV types cause the remaining 25-40% of cervical cancers.2 85 
With increasing severity of the cervical abnormality, attributable fractions due to HPV16 and 86 
HPV18 increase while those due to other types concomitantly decrease.3 87 
CIN2 has been the threshold for cervical treatment, by either excision or ablative 88 
treatment.4 However, recently there has been an increasing recognition that the H&E diagnosis 89 
of CIN2 is an equivocal diagnosis with significant inter-observer variability and likely represents 90 
an admixture of (misclassified) HPV infection/CIN1 and precancer (CIN3)5 rather than a 91 
biological intermediate step in the progression from CIN1 to CIN3 as was originally thought.6 92 
The uncertainty of the meaning of this diagnosis is perhaps reflected in its poor diagnostic 93 
reproducibility between pathologists.7-11 Because CIN2 likely has overall low immediate 94 
potential to become invasive cancer, frequently regresses especially in young women (aged <30 95 
years)12, and excisional treatment is possibly associated with an increased risk of preterm 96 
delivery13, 14, current management guidelines in the United States (U.S.) recommend “wait and 97 
watch” rather than treatment for CIN2 diagnosed in young women (aged <30 years) of 98 
reproductive potential when the squamocolumnar junction can be visualized in its entirety.4 99 
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There has been great interest in using adjunctive biomarkers to improve the classification 100 
and reliability of histopathologic diagnoses, based on hematoxylin and eosin (H&E) staining, of 101 
cervical abnormalities, especially to reduce the over-diagnosis of CIN2 on H&E, clarify the 102 
clinical significance of CIN2 (i.e., distinguish between benign CIN2 diagnoses potentially 103 
destined to regress or not progress from CIN2 diagnoses that reflect the presence of high-grade 104 
cervical abnormalities that, for safety against cancer, should be treated to reduce the risk of 105 
cancer development.). Some of the biomarkers investigated for clarifying the meaning of an 106 
H&E diagnosis of  CIN2 on biopsy include (but are not limited to) HPV1615, HPV L116, 17, Ki-107 
677, 16, E418, 19, and p16INK4a (p16)7, 11, 16 detection. 108 
Immunohistochemistry (IHC) for in situ detection of p16 (p16 IHC) has emerged as an 109 
adjunctive biomarker to aid in the diagnosis of cervical abnormalities. p16 IHC has been shown 110 
to be sensitive for CIN2 and CIN37, 14 and its interpretation is much more reliable/reproducible 111 
than morphology based on H&E staining alone.11, 20, 21 Recommendations from the Lower 112 
Anogenital Squamous Terminology (LAST) Standardization Project include the use of p16 IHC 113 
in the following specific circumstance22: “If the pathologist is entertaining an H&E morphologic 114 
interpretation of –IN 2 (under the old terminology, which is a biologically equivocal lesion 115 
falling between the morphologic changes of HPV infection [low-grade lesion] and high-grade 116 
cervical abnormalities), p16 IHC is recommended to help clarify the situation. Strong and diffuse 117 
block-positive p16 IHC results support a categorization of precancer. Negative or non-block-118 
positive staining strongly favors an interpretation of low-grade disease or a non-HPV-associated 119 
pathology.” LAST recommended a switch from the three-tier categorization, CIN1, CIN2, and 120 
CIN3, to a two-tier system of categorization of low-grade squamous intraepithelial lesion (LSIL), 121 
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which includes CIN1 and p16 IHC-negative CIN2, and high-grade squamous intraepithelial 122 
lesion (HSIL), which includes CIN3 and p16 IHC-positive CIN2. 123 
However, the question remains about whether p16 IHC distinguishes between benign 124 
HPV infection and clinically significant CIN2 i.e., those that have or will develop invasive 125 
potential thereby representing a high-grade cervical abnormality. Obviously, it is not logistically 126 
or ethically possible to follow a cohort of women diagnosed with CIN2 to see who develops 127 
cervical cancer to answer this question, as was done tragically with CIN3/carcinoma in situ.23 128 
The subsequent diagnosis of CIN3 in follow-up of CIN2 cases may not be true progression but 129 
rather a correction of a previously misclassified CIN2 diagnosis and sampling errors including 130 
missed CIN3 at colposcopy.  131 
To better understand the cervical-cancer risk stratification achieved by p16 IHC for 132 
routine diagnoses (community pathology [CP]) of CIN2 as well as other diagnosis, we conducted 133 
a large U.S. population-based study of p16 IHC and its relationship to other biomarkers of 134 
cervical-cancer risk, including an expert panel (EP) consensus review that has been shown to 135 
improve the certainty of high-grade cervical abnormalities and therefore the association with 136 
HPV24, tissue HPV genotyping, and antecedent cytology result. Increasing severity of histologic 137 
diagnosis rendered by an EP review of a CP diagnosis of CIN2 is associated with a CIN3 138 
diagnosis on tissue from an excision procedure.25 The percent positive for the highest risk HPV 139 
genotypes, especially HPV16, increases with the severity of cervical diagnosis3, 25, and the HPV 140 
genotype(s) detected in the diagnostic tissue generally is considered the cause of the cervical 141 
abnormality. Cytologic interpretations of high-grade squamous intraepithelial lesion (HSIL) or 142 
more severe (HSIL+) are more strongly associated with histologically confirmed CIN3 and 143 
cancer than less severe cytologic interpretations, and antecedent HSIL often proceeds rare cases 144 
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of invasive cervical cancer in the follow-up of women diagnosed with CIN2 and under 145 
surveillance (vs. immediate treatment).26, 27 HSIL cytology is of sufficient clinical concern that 146 
treatment is considered acceptable even without histologic confirmation of CIN2 or more severe 147 
diagnoses (CIN2+) on biopsy.4 148 
Our main goal was to assess whether biopsy diagnosed as CIN2 by morphology and 149 
tested positive for p16 by IHC was similar enough to biopsy diagnosed CIN3 in the distribution 150 
of these other biomarkers of cervical cancer risk such that making a distinction between the two 151 
would be unnecessary i.e., calling both HSIL without annotating the morphologic diagnosis of 152 
CIN2 or CIN3.  153 
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METHODS 154 
Cervical biopsies used in the current study were part of a previous population-based 155 
study.10 The biopsy with the most severe diagnosis of individual women diagnosed in the period 156 
of 2006-2009 was used. Of the 21,297 women diagnosed in laboratories serving New Mexico’s 157 
residents during the study period, a stratified sample of 6,272 women was chosen to over-158 
represent CIN2 and CIN3 for additional characterization. This sample included 90.1% of all 159 
CIN2+ diagnosed, which represented all adequate CIN2+ biopsies that could be found, and 160 
random samples of 17.7% of all CIN1 and 6.3% of all negative histology biopsies diagnosed 161 
during that period. 162 
Laboratory Testing 163 
A “sandwich” technique was employed to enable histopathologic review of tissue 164 
sections flanking the sections subjected to HPV genotyping and p16 IHC as follows: One four 165 
micron (4 μM) section was obtained for H&E staining, two 4 μM sections for HPV genotyping 166 
were collected into o-ringed microfuge tubes, a second 4 μM section was obtained for H&E 167 
staining, and then 4μM section(s) adjacent to this second H&E were obtained for biomarker 168 
staining including p16 IHC with sections collected onto Fisherbrand Superfrost Plus glass slides. 169 
Selection of the cases for the current study was limited to those in which 5 or more 170 
unstained slides were available to allow for potential unsatisfactory slides and the opportunity for 171 
further tests on the same subset. This resulted in a group of 4,359 cases from which 4,100 172 
biopsies from different women were selected randomly to create 41 sets of 100 slides, each of 173 
which was reviewed by one of 41 different pathologists participating in this study as volunteers 174 
(p16 IHC Study Group). Patient age and, when available, referral cytology (3,563, 86.9% of 175 
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cases) were also provided to the pathologists. p16 IHC was performed, as described below, on an 176 
unstained slide adjacent to the H&E stained slide used for diagnosis from each case. Each set 177 
contained similar proportions of each diagnostic outcome.  178 
p16 IHC. Formalin-fixed, paraffin-embedded (FFPE) cervical tissue sections were 179 
stained using one of two methods; manually using the CINtec Histology Kit (Roche mtm 180 
laboratories) or using the automated BenchMark instrument platform (Ventana/Roche). Briefly, 181 
de-paraffinization was performed by baking the slides at 65°C for 45 minutes followed by 182 
rehydration of the tissues in xylene and graded alcohol baths (95%, 70%, and 50%). Optimized 183 
epitope retrieval for archival tissues was performed at 95°C for 45 minutes in epitope retrieval 184 
solution. Epitope retrieval slides were either transferred to the BenchMark XT or manually 185 
stained. The p16 IHC staining and visualization procedures followed the BenchMark p16 IHC 186 
protocol or the CINtec Histology Kit protocol specified by the manufacturer. 187 
HPV genotype detection in FFPE tissues. Methods for HPV genotyping of the FFPE 188 
tissue sections were previously reported and are summarized here.28 FFPE tissue sections were 189 
digested in a protein K (PK) digestion buffer at 65°C for 4 hours followed by overnight at 37°C. 190 
Prior to polymerase chain reaction (PCR)-based HPV genotyping, digested FFPE tissue was 191 
heated at 95°C for 15 minutes to inactivate the PK and centrifuged briefly at 13,000 × g to 192 
remove undigested material, and the supernatant (aqueous digest) was decanted and stored at -193 
80°C until tested. 194 
Two and five μL (for two separate genotyping determinations) of the aqueous digest from 195 
each tissue specimen were used for genotyping with the LINEAR ARRAY HPV Genotyping 196 
Test (HPV LA; Roche Diagnostics, Indianapolis, Indiana USA), a qualitative HPV genotyping 197 
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test for 37 HPV genotypes.29-31 Using the Roche LA HPV detection kit, hybridizations were 198 
automated using Tecan ProfiBlot-48 robots (Tecan, Grödig, Austria) as previously described.32 199 
The Roche LA HPV Genotyping Test detects 13 high- and 24 low-risk HPV types. HPV52 is not 200 
determined directly by a type-specific probe but by inference as previously described.28, 31 Two 201 
independent readers interpreted the presence of HPV genotypes using a reference template and 202 
any differences between the two readers were adjudicated by a third independent reader. The 203 
adjudicated result was taken as the final interpretation. 204 
Pathology Reviews 205 
EP Reviews. EP pathologists rendered an adjudicated consensus diagnosis of these 206 
biopsies.10 The EP diagnosis review was based only on an H&E staining of a new section and 207 
masked to any other data including p16 IHC results when available. 208 
Volunteer Pathologist (VP) Reviews. 41 pathologists (p16 IHC Study Panel Group; here 209 
referred to as VP) practicing throughout the United States (US) and Canada agreed to review the 210 
H&E and p16 IHC for 100 cervical biopsies each. Recruitment of VP pathologists was either via 211 
direct invitation for College of American Pathologist committee members or through general 212 
advertisement (e.g. flyers) at professional society meetings.  213 
VPs were given a two-page instructions sheet developed by Ventana to guide their 214 
interpretation of p16 IHC. Diffuse p16 IHC staining was considered positive (“A continuous 215 
staining of cells of the basal and parabasal cell layers of the cervical squamous epithelium, with 216 
or without staining of the intermediate or intermediate to superficial cell layers.”). p16 IHC 217 
resulting in a focal (“Either a staining of isolated cells or small cell clusters; i.e., a non-218 
continuous staining, particularly not of the basal and parabasal cells.”) or negative (“the p16 219 
12 
 
stained slide shows no staining reaction”) staining pattern were considered negative.  Only the 220 
p16 IHC interpretations of the VP were used in theses analyses. 221 
The p16 IHC interpretations of the VP were used whereas morphologic diagnoses of the 222 
VP, though performed for studies of p16 utilization, were not included in these analyses. Use of 223 
p16 interpretations rendered by the independent VP was preferred to reduce inherent 224 
interpretation biases when comparing community and EP diagnoses. 225 
Analysis 226 
The primary aim of the analysis was to examine whether the CP-diagnosed CIN2 that 227 
subsequently tested p16-IHC positive was the risk equivalent to the CP-diagnosed CIN3, which 228 
is routinely treated in clinical practice. Thus, the CP diagnoses, with and without stratification by 229 
p16 IHC as read by the VP, were compared to the EP diagnoses (masked to p16 IHC results), 230 
tissue HPV genotyping, and antecedent cytologic interpretations. 231 
Of the statewide sample of 21,297 cervical biopsies, there were 21,187 cervical biopsy 232 
tissues after excluding AIS, adenocarcinoma, and cancers other than squamous cell carcinoma 233 
(SCC) histology. A consort diagram of the biopsies included in this analysis is shown in Figure 234 
1. Sampling fractions of the statewide population for each grade of biopsy diagnosis by the CP 235 
used in these analyses are shown in Supplemental Table 1 for reference. For simplicity, these 236 
analyses did not correct for sampling fractions (of the CP diagnoses) (except where otherwise 237 
noted) as all CIN2+ biopsies that could be located were collected and were assumed to be 238 
representative i.e., cases were missing at random. A random sample of CP-diagnosed negative 239 
and CIN1 histology were included from the entire state of New Mexico. 240 
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Of the 4,100 samples tested by p16 IHC, 65 were excluded (from above) from this 241 
analysis because they were diagnosed by CP as glandular disease, adenocarcinoma in situ or 242 
adenocarcinoma, which are not included in the LAST recommendations. An additional 25 were 243 
classified as “Technically Unsatisfactory” by any (CP, EP, and/or VP) pathology review, thus 244 
excluded. As noted, the distribution of HPV genotypes causing squamous cell carcinoma (SCC) 245 
were included for reference under the assumption that the more closely the profile of biomarkers 246 
for a precursor diagnosis resembled SCC, the better proxy it was for cancer risk i.e., high-grade 247 
cervical abnormalities with invasive potential. After the aforementioned exclusions, the resulting 248 
sample size was 4,010. 249 
HPV genotype results were categorized hierarchically according to their a priori cancer 250 
risk2, 3, 33 for simplicity of presentation and to account for detection of multiple HPV genotypes: 251 
1) HPV16 positive; 2) HPV16 negative and HPV18 and/or HPV45 (HPV18/45) positive, 3) 252 
HPV16, 18, and 45 negative and HPV31, 33, 35, 39, 51, 52, 56, 58, 59, and/or 68 positive (other 253 
high-risk HPV) positive, 4) negative for all high-risk HPV types and HPV26, 53, 66, 67, 70, 73, 254 
and/or 82 (intermediate risk HPV) positive, 5) high- or intermediate-risk HPV negative and 255 
HPV6, 11, 40, 42, 54, 55, 61, 62, 64, 69, 71, 72, 81, 82v, 83, 84, and/or 89 (low-risk HPV) 256 
positive, or 6) HPV negative for all measured types. A shift in a distribution to higher- or lower- 257 
HPV risk groups was considered to be related to a greater or lesser risk of cervical cancer, 258 
respectively.  259 
 The proportion and binomial exact 95% confidence interval (95%CI) of p16 IHC positive 260 
by grade of biopsy diagnosis by CP was calculated. A non-parametric test of trend34 or Trend test 261 
using weighted logistic regression model was used to test for trends in p16-IHC or HPV risk 262 
groups within or between diagnostic categories by the CP or EP. Trends in the percent p16-IHC 263 
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positive, HPV16 positive, and with an antecedent HSIL+ cytology, according to The Bethesda 264 
System for cytologic classification35, for paired CP and EP diagnoses were calculated. The 265 
percent p16-IHC positive, HPV16 positive, with an antecedent HSIL+ cytology, and with 266 
cervical intraepithelial neoplasia grade 3 or more severe (CIN3+) or CIN2+ diagnosed by the EP 267 
was compared between p16 IHC-negative and –positive CIN2 and between p16 IHC-positive 268 
CIN2 and CIN3 diagnosed by the CP using a Fisher’s exact test. Finally, trends in HPV risk 269 
groups were compared for CIN2 diagnosed by the CP for all 4 combinations of cytology results 270 
(<HSIL vs. HSIL+) and p16 IHC results (negative and positive). 271 
P values of <.05 were considered significant. STATA (Versions 13.1 and 15.1; StataCorp 272 
LLC, College Station, TX, USA) were used for analyses.  273 
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RESULTS 274 
Correlations of HPV categories, p16 IHC results, and histologic diagnosis by the CP are 275 
shown in Table 1. The percent p16 IHC positive increased with an increasing severity of 276 
histologic diagnoses by the CP: 7.4% (95%CI = 4.7%-11.1%) for negatives, 26.6% (95%CI = 277 
23.7%-29.5%) for CIN1, 71.9% (95%CI = 69.6%-74.2%) for CIN2, and 90.7% (95%CI = 278 
88.9%-92.2%) for CIN3 (Ptrend<.001); for reference, 94.5% (95%CI = 86.6%-98.5%) of the 279 
squamous cell carcinomas (SCC) tested p16-IHC positive. The percent p16-IHC positive 280 
increased with an increasing severity of biopsy diagnosis by the CP for each HPV risk group 281 
(i.e., HPV16 > HPV18/45 > other high-risk HPV > intermediate-risk HPV > low-risk HPV > 282 
HPV negative) (Ptrend≤.001). The percent p16-IHC positive increased with an increasing severity 283 
of biopsy diagnosis by the CP even among HPV negatives (Ptrend<.001), suggestive of some 284 
false-negative HPV genotyping. The percent p16-IHC positive increased with higher-risk HPV 285 
groups for each diagnosis (Ptrend<.001). Testing p16 IHC positive was associated with higher 286 
HPV risk group than testing p16 IHC negative for each grade of CP-diagnosed biopsies 287 
(P<.001). That is, both HPV genotype and histologic diagnosis were independent determinants 288 
of testing p16 IHC positive. 289 
We found no meaningful differences in the distribution of HPV genotypes detected or 290 
p16-IHC results based on the study sub-sample compared to those same results when 291 
extrapolated to the whole sample (Supplemental Table 2). HPV genotype-specific results 292 
stratified by the CP diagnosis and p16-IHC results are presented in Supplemental Table 3.  293 
For all abnormal histology (CIN1 or more severe), p16 IHC-positive cases had higher-294 
risk HPV than p16 IHC-negative diagnoses. Notably, p16 IHC-positive CIN2 had lower-risk 295 
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HPV than CIN3 (Ptrend<.001); 38.2% (415 of 1,087) of p16 IHC-positive CIN2 tested positive for 296 
HPV16 whereas 54.5% (658 of 1,208) of all CIN3, regardless of the p16 IHC, tested positive for 297 
HPV16. p16 IHC-negative CIN2 had lower-risk HPV than p16 IHC-positive CIN2 (Ptrend<.001) 298 
but higher-risk HPV than all CIN1 (Ptrend<.001), p16 IHC positive CIN1 (P<.001), or negative 299 
histology (Ptrend<.001) (i.e., regardless of the p16 IHC). 300 
p16 IHC-positive CIN3 had higher-risk HPV than p16 IHC-negative CIN3 (Ptrend<.001). 301 
p16 IHC-positive CIN3 was less likely to test positive for HPV18/45 (P<.001) than SCC, again 302 
demonstrating that HPV18/45 tends to under-represented in CIN3 compared to its attributable 303 
fraction in SCC.3, 36, 37 p16 IHC-negative CIN3 had higher-risk HPV than p16 IHC-positive 304 
CIN2 (Ptrend=.02). Similar patterns of p16 IHC and HPV risk groups were observed for the EP 305 
(Supplemental Table 4). 306 
Table 2 shows the pair-wise diagnoses by the CP and EP and the correlation with testing 307 
p16 IHC positive or HPV16 positive, or having an antecedent HSIL+ cytology. Increasing 308 
severity of the EP diagnosis for a given CP diagnosis, and vice versa, was associated with 309 
increased likelihood of the biopsy testing p16-IHC positive or HPV16 positive (Ptrend<.001 for 310 
both), with exception for when SCC was diagnosed by either the CP or the EP, or negative by the 311 
CP (Ptrend<.001 for p16 IHC and Ptrend=.40 for HPV16). Increasing severity of the CP diagnosis 312 
for a given EP diagnosis was also increasingly likely to have an antecedent HSIL+ cytology 313 
(Ptrend<.001 for negative, CIN1, CIN2, and CIN3 and p=.05 for SCC). Increasing severity of the 314 
EP diagnosis for a CP diagnosis of CIN3 was more likely to have an antecedent HSIL+ cytology 315 
(Ptrend<.001). Surprisingly, increasing severity of the EP diagnosis for a CP diagnosis of 316 
negative, CIN2, and cancer was not associated with having an antecedent HSIL+ cytology 317 
(Ptrend>.05 for all). 318 
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Table 3 compares percent HPV16 positive, antecedent HSIL+ cytology, and CIN3+ and 319 
CIN2+ diagnosis by the EP between CP-diagnosed CIN2, stratified on p16 IHC status, and 320 
CIN3. p16 IHC-positive CIN2 was less likely than CIN3 to test HPV16 positive (38.18% vs. 321 
54.47%, respectively, P<.001), have an antecedent HSIL+ cytology (21.02% vs. 42.53%, 322 
respectively, P<.001), or be diagnosed on review by the EP as CIN3+ (22.91% vs. 65.31%, 323 
respectively, P<.001) or CIN2+ (64.40% vs. 88.08%, respectively, P<.001). p16 IHC-positive 324 
CIN2 was less likely than CIN3 to be positive for at least one of these biomarkers (HPV16, 325 
antecedent HSIL+ cytology, and/or CIN3+ diagnosed by EP) (58.23% vs. 85.93%, respectively, 326 
P<.001). p16 IHC-positive CIN2 was less likely than CIN3 to be positive for all three 327 
biomarkers (2.48% vs. 15.89%, respectively, P<.001). p16 IHC-negative CIN2 was less likely 328 
than p16 IHC-positive CIN2 to be positive for any individual biomarker (P<.001), with 329 
exception of having antecedent HSIL+ cytology (P>.99). p16 IHC-negative CIN2 was less likely 330 
than p16 IHC-positive CIN2 to be positive for at least one biomarker (P<.001) or all three 331 
biomarkers (P<.001). 332 
Table 4 compares the HPV risk group distribution for CP-diagnosed CIN2 that tested 333 
p16 IHC negative or positive and antecedent less than HSIL cytology (<HSIL) or HSIL+ 334 
cytology. Notably, p16 IHC-positive CIN2 with an antecedent HSIL+ cytology has lower risk 335 
HPV than all CP-diagnosed CIN3 (P=.01), p16 IHC-negative CIN2 with an antecedent <HSIL 336 
cytology has higher risk HPV than all CP-diagnosed CIN1 (P<.001).  337 
18 
 
DISCUSSION 338 
In the largest case series to include HPV genotyping and p16 IHC immunostaining of 339 
biopsies to date, we were able to show the detailed relationship of these biomarkers with 340 
community diagnoses of precursors to cervical cancer, with a focus on CIN2. Key observations 341 
from our analyses were: 1) most CP-diagnosed CIN2 and CIN3, and a significant proportion of 342 
CIN1, tested p16-IHC positive; 2) p16 IHC-positive, CP-diagnosed CIN2 was less likely to test 343 
HPV16 positive, to have an antecedent HSIL+ cytology, and to be called CIN3+ or CIN2+ by 344 
the EP than CP-diagnosed CIN3; 3) p16 IHC-negative CIN2 had lower-risk HPV than p16 IHC-345 
positive CIN2 but higher-risk HPV than CIN1; and 4) p16 IHC-negative CIN3 had higher-risk 346 
HPV than CIN2 or even p16 IHC-positive CIN2. 347 
These data also confirm that p16 IHC corrects some of the errors in diagnosing high-348 
grade cervical abnormalities but does so imperfectly. Approximately 28% of the CP-diagnosed 349 
CIN2 tested p16-IHC negative in this study; other studies have reported the percentage of p16 350 
IHC-negative CIN2 ranging from approximately 20%16 to less than 10%.21, 38 Based on HPV risk 351 
group distribution, these cases were indeed lower risk and are less likely to progress to cancer. 352 
That is, p16 IHC-negative, CP-diagnosed CIN2 was more like CIN1 than CIN3. It is therefore 353 
justifiably to down-grade p16 IHC-negative, CP-diagnosed CIN2 to LSIL as recommended by 354 
LAST.22 Conversely, p16 IHC-positive, CP-diagnosed CIN2 was more like CP-diagnosed CIN3 355 
than CIN1. 356 
However, these data also indicate that some fraction of the p16 IHC-positive, CP-357 
diagnosed CIN2 is not a high-grade cervical abnormality. The implication of these data is that if 358 
LAST terminology22 is to be used in routine practice (equivalent to CP), the use of HSIL 359 
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categorization for CIN3 or p16 IHC-positive CIN2 must include annotation of the H&E 360 
(morphologic) diagnosis, e.g., HSIL(CIN3) or HSIL(CIN2), respectively, which was suggested  361 
as optional by LAST. It is clear from these data that p16 IHC-positive CIN2 is NOT the clinical 362 
equivalent of CIN3. That is, a p16 IHC-positive CIN2 does not have the same clinical meaning 363 
(invasive potential) as CIN3, and therefore the two cannot be considered one clinical entity and 364 
should not be conflated with one another. When EP diagnosed the CP-diagnosed CIN2 biopsy as 365 
CIN3, the fraction that tested HPV16 and p16 IHC positive was close to that of the CP-366 
diagnosed CIN3 biopsy, suggesting that these were high-grade cervical abnormalities. However, 367 
a consensus review by a panel of expert pathologists is not typically available in routine clinical 368 
practice. 369 
Recent reports confirm the dramatic difference in risk of subsequent invasive cancer 370 
between CIN212,28 and CIN323 diagnoses. The disparity in HPV genotype distribution that we 371 
report provides a credible biologic explanation for this difference. Moreover, our findings 372 
emphasize that making this distinction between CIN2 and CIN3 for a HSIL diagnosis is 373 
necessary for clinical decision-making on whether to treat women with precursor lesions that 374 
might otherwise regress on their own. This is especially true in young women diagnosed with 375 
CIN2 for whom conservative management (wait and watch) is preferred4 due possibly to the 376 
possibility of added risk of negative reproductive outcomes (e.g., preterm delivery) associated 377 
with excision treatments.13, 14 Much of p16 IHC-positive CIN2 is likely to regress on its own, 378 
given that approximately 70-80% of CIN2 tests p16 IHC positive16, 39, as observed here, but 379 
approximately 50% of all CIN2, and approximately 60% of CIN2 diagnosed in women under the 380 
age of 30 years, will regress.12 Arithmetically, even if all p16 IHC-negative CIN2 was regressive, 381 
a significant proportion of p16 IHC-positive CIN2 must also be regressive. A prospective study 382 
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of women diagnosed with CIN2 reported that 57% of p16 IHC-positive CIN2 regressed in 12 383 
months.39 Retrospective study of women diagnosed with pathology review-confirmed CIN2 384 
followed for two years found that 50% of regressive CIN2 were initially p16 IHC positive and 385 
18% of p16 IHC-positive lesions regressed.40 386 
In addition to causing the unnecessary treatment of some women with CIN2, losing the 387 
distinction between (p16-positive) CIN2 and CIN3 would also have long-term negative 388 
implications on the opportunity for future improvements to the diagnosis of high-grade cervical 389 
abnormalities. As new biomarkers are being developed that might better distinguish between 390 
HPV infection and high-grade cervical abnormalities and therefore might be applied to CIN2 or 391 
even p16 IHC-positive CIN2, it will be important to be able to easily identify such cases by 392 
qualifying whether they were diagnosed as CIN2 or CIN3. 393 
These data also underscore the importance of the LAST recommendation not to perform 394 
p16 IHC testing systematically on all CIN3 or CIN1.22 For CP-diagnosed CIN3, less than 10% of 395 
community diagnoses of CIN3 tested p16 IHC negative. CP-diagnosed CIN3 that tested p16 IHC 396 
negative had a less risky HPV group distribution (Ptrend<.001) but were similarly likely to have 397 
antecedent high-grade cytology (25.5% vs. 24.8%, P=.89) as CP-diagnosed CIN2 that was 398 
diagnosed as CIN3 by the EP. Thus, p16 IHC-negative CIN3 is unlikely to be at sufficiently low 399 
risk to change its management i.e., there is no clinical utility, only added cost, to systematically 400 
using p16-IHC on CIN3 diagnoses. 401 
Nor is there evidence that p16 IHC testing of CIN1 provides clinically meaningful risk 402 
stratification or predicts progression to CIN2+ as previously shown.41-43 Here, based on HPV risk 403 
group distribution, p16 IHC-positive CIN1 was higher risk than p16 IHC-negative CIN1 but not 404 
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even as high risk as p16 IHC-negative CIN2. Moreover, p16 IHC-positive CIN1 was similarly 405 
unlikely to have an antecedent high-grade cytology as p16 IHC-negative CIN1 (3.2% vs. 5.1%, 406 
respectively, P=.27) (data not shown). 407 
Aside from the added cost for limited or no benefit to women diagnosed with CIN1, p16-408 
IHC testing of biopsies diagnosed as CIN1 might result in incorrect, over-interpretation of a 409 
positive p16-IHC result as CIN2, which could then lead to unnecessary treatment and a 410 
concomitant increased risk of preterm delivery for those still considering childbearing.13, 14, 42 411 
Limited p16 IHC testing, and/or possibly Ki-67 IHC testing, of some CIN1 might have 412 
some value for internal use as a laboratory quality control standard7, 44, similar to the use of 413 
HPV:SIL rates for cytology45, to set the threshold of normal vs. non-normal histology. We 414 
observed that approximately one-quarter of the CP-diagnosed CIN1 tested p16-IHC positive in 415 
this study. Other studies have reported a percent p16-IHC positive for CIN1 ranging from 416 
approximately 10% to almost 60%16, 21, 42, 46-50, suggesting significant variability/unreliability in 417 
the morphologic interpretation of diagnosis criteria for CIN1 (vs. negative or CIN2) compared to 418 
a more objective standard i.e., p16 IHC. 419 
 Likewise, some pathologists equivocate between CIN1 and CIN2 or diagnosis “CIN1/2”. 420 
We did not separately analyze cases of CIN1/2 as there were small numbers in our dataset. 421 
However, the LAST recommendation for using p16 IHC was to clarify the clinical meaning of 422 
CIN2 by distinguish those CIN2 that were higher risk (p16 IHC-positive CIN2) from those that 423 
were lower risk (p16 IHC-negative CIN2), not to clarify meaning of CIN1. Here again, there 424 
would be potential for over-utilization of p16 IHC. Pathologists uncertain whether a biopsy 425 
diagnosis is CIN1 or CIN2 might be tempted to call it CIN1/2 or even CIN2 for perceived 426 
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greater safety, believing that using p16 IHC as an adjunctive test would correct any overcalls. 427 
However, because such a high percentage of CIN1 (and therefore also “CIN1/2”) will also test 428 
p16 IHC positive, most of which is nothing more than low-grade, benign, regressive CIN1, these 429 
biopsies might then get misclassified as HSIL and women would receive unnecessary treatment. 430 
 A few other scenarios might exacerbate the inappropriate use of p16 IHC on CIN1 431 
biopsies. First, pathologists, worried that future review of a CIN1 biopsy by second pathologist 432 
might result in a CIN2 diagnosis, might be motivated to do p16 IHC on a CIN1 or a CIN1/2 that 433 
previously they would report as CIN1. In addition, p16 IHC on CIN1 or CIN1/2 may be used by 434 
pathologists as feedback to lower their criteria for a CIN2 diagnosis resulting in more CIN1 435 
being called CIN2. 436 
We acknowledge an important limitation: this analysis was cross-sectional and therefore 437 
we could only make inferences related to true cervical cancer risk based on biomarker 438 
distributions. Nevertheless, these biomarkers included in this analysis are strong predictors of 439 
cervical cancer risk and if practical, could be incorporated into improved diagnostic 440 
classification of cervical abnormalities. Indeed, women whose Pap specimen was called high-441 
grade cytology and tested HPV16 positive (the read out for which is provided by some HPV tests 442 
vs. setting up laboratory testing of biopsies) are at very high risk of CIN3, up to ~80%.51, 52 443 
Another potential limitation is that the EP diagnoses were based on H&E alone and were 444 
not informed by p16 IHC results. However, it is unknown whether p16-IHC informed 445 
interpretations of H&E diagnoses would have resulted in improved classification of CIN2 vs. 446 
H&E diagnosis rendered independently of p16 IHC results.  447 
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Future studies in cohorts with long-term follow-up will be needed to determine the risk 448 
stratification provided by p16-IHC testing of CIN2. These cohorts will need to be rather large 449 
because of the rarity of CIN2 (<1%) in the general population and losses to follow-up. 450 
Alternatively, retrospective analyses of conservatively managed CIN2 in younger women could 451 
be done in which the index CIN2 biopsies are tested by p16 IHC. Such studies would provide 452 
important information on its risk stratification, how safe (vs. invasive cancer) women with p16 453 
IHC-negative CIN2 are, and how much over-treatment is likely to occur if p16 IHC-positive 454 
CIN2 were to be treated immediately. 455 
It is clear from these and other data that p16 IHC is a sensitive but non-specific 456 
biomarker of CIN3, which is a more rigorous definition of “cervical precancer” than CIN2 and 457 
even p16 IHC-positive CIN2. Even so, many but not all CIN3 will develop into invasive cervical 458 
cancer if left untreated.23 However, because of the lack of specificity of p16 IHC, presumably 459 
due to its increased expression in response to productive HPV infections that may or may not 460 
progress53, 54, many low-grade cervical abnormalities will still test p16-IHC positive even if they 461 
are not destined to progress to high-grade cervical abnormalities. LAST classification of “HSIL” 462 
diagnosis, which includes p16 IHC-positive CIN2, should annotate the morphologic diagnosis of 463 
CIN2 or CIN3 in routine clinical practice to inform all clinical management decisions. This is 464 
especially important for (but not limited to) those women under the age of 30 years and/or 465 
considering childbearing and diagnosed with CIN2 for whom surveillance rather than treatment 466 
is recommended4 and/or desirable, respectively. While neither “biomarker”, CIN diagnosis or 467 
p16 IHC, is perfect, together they further stratify the cervical cancer risk and if used correctly 468 
better inform clinical decision making than either can accomplish alone. 469 
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In summary, there is currently no reliable way to distinguish those CIN2 and even p16 470 
IHC-positive CIN2 diagnoses that will progress or regress. The use of other biomarkers with or 471 
without p16 IHC may improve the diagnostic classification of cervical abnormalities in relation 472 
to their invasive cancer potential. 473 
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Table 1. Human papillomavirus (HPV) genotyping results, categorized according to cervical-cancer risk, and p16 immunohistochemistry (IHC) 
results (p16 IHC positive [p16+] or negative [p16-]) for biopsy diagnosis by the community pathology (CP) biopsy diagnoses of negative, CIN1, 
CIN2, and CIN3. Results for all squamous cell carcinoma (SCC) are shown for reference. “%Col” is the column percentage i.e., the number in cell 
divide by the total column number. 
Diagnosis: Negative CIN1 CIN2 CIN3  SCC 
 p16-IHC 
Negative 
p16-IHC 
Positive 
p16-IHC 
Negative 
p16-IHC 
Positive 
p16-IHC 
Negative 
p16-IHC 
Positive 
p16-IHC 
Negative 
p16-IHC 
Positive 
 All 
HPV Categories‡ N %Col N %Col N %Col N %Col N %Col N %Col N %Col N %Col ptrend† N %Col 
HPV16 8 3.1 1 4.8 32 4.7 35 14.1 91 21.4 415 38.2 41 36.3 617 56.3 <.001 43 58.9 
HPV18/45 5 1.9 2 9.5 24 3.5 25 10.1 29 6.8 82 7.5 8 7.1 57 5.2 <.001 10 13.7 
Other High-Risk* 21 8.0 7 33.3 142 20.7 128 51.6 163 38.4 496 45.6 36 31.9 354 32.3 <.001 10 13.7 
Intermediate Risk** 9 3.4 2 9.5 54 7.9 28 11.3 29 6.8 56 5.2 3 2.7 31 2.8 <.001 2 2.7 
Low-Risk¥ 4 1.5 0 0.0 35 5.1 4 1.6 18 4.2 7 0.6 4 3.5 3 0.3 .0097 1 1.4 
HPV Negative 215 82.1 9 42.9 399 58.2 28 11.3 95 22.4 31 2.9 21 18.6 33 3.0 <.001 7 9.6 
Total 262 100 21 100 686 100 248 100 425 100 1,087 100 113 100 1,095 100 <.001 73 100 
ptrend§ = <.001 <.001 <.001 <.001    
‡Defined hierarchically according to cancer risk 
†test of trend for testing p16 IHC positive across diagnoses (excluding cancer) for each HPV risk group 
*HPV31, 33, 35, 39, 51, 52, 56, 58, 59, and 68 
**HPV26, 53, 66, 67, 70, 73, and 82 
¥HPV6, 11, 40, 42, 54, 55, 61, 62, 64, 69, 71, 72, 81, 82v, 83, 84, and 89 
§test of trend for HPV risk group by p16 IHC result for each diagnosis  
28 
 
Table 2. Pairwise diagnoses by the community pathology (CP) and expert panel (EP) and the percent p16 immunohistochemistry (IHC) positive 
(%p16 IHC+), human papillomavirus type 16 (HPV16) positive (HPV16+), and with an antecedent high-grade squamous intraepithelial lesion 
(HSIL) or more severe (HSIL+) cytologic interpretation. “%cell” is the cell percentage i.e., Ncell/Ntotal. 
   Expert Panel (EP) Diagnosis     
   Negative CIN1 CIN2 CIN3 SCC Total ptrend 
(p16) 
ptrend 
(HPV16) 
ptrend 
(HSIL+ Cytology) 
C
o
m
m
u
n
it
y
 P
a
th
o
lo
g
y
 (
C
P
) 
D
ia
g
n
o
si
s 
Negative 
N 261 14 7 1 0 283 
.009 .40 .15 
%cell 6.53 0.35 0.18 0.03 0.00 7.08 
%p16 IHC+ 6.51 7.14 42.86 0.00 0.00 7.42 
%HPV16+ 3.07 0.00 14.29 0.00 0.00 3.18 
%HSIL+ Cytology* 7.58  33.33  14.29  0.00 0.00 8.84 
CIN1 
N 535 318 67 11 0 931 
<.001 <.001 .029 
%cell 13.39 7.96 1.68 0.28 0.00 23.29 
%p16 IHC+ 10.47 42.77 68.66 81.82 0.00 26.53 
%HPV16+ 3.74 11.32 16.42 0.00 0.00 7.20 
%HSIL+ Cytology** 5.93  3.25  1.56  0.00  0.00  4.62 
CIN2 
N 260 431 547 271 0 1509 
<.001 <.001 .43 
%cell 6.50 10.78 13.69 6.78 0.00 37.75 
%p16 IHC+ 34.23 68.68 82.45 91.88 0.00 71.90 
%HPV16+ 18.46 24.59 40.04 47.97 0.00 33.33 
%HSIL+ Cytology§ 23.45  17.66  20.80  24.80 0.00  21.08 
CIN3 
N 90 48 275 787 2 1202 
<.001 <.001 <.001 
%cell 2.25 1.20 6.88 19.69 0.05 33.07 
%p16 IHC+ 42.22 70.83 89.45 97.71 100.00 90.60 
%HPV16+ 33.33 25.00 49.45 60.36 50.00 54.41 
%HSIL+ Cytology† 27.50  31.82  34.60 47.74  0.00  42.50 
SCC 
N 1 0 2 17 52 72 
.010 .36 .17 
%cell 0.03 0.00 0.05 0.43 1.30 1.80 
%p16 IHC+ 0.00 0.00 100.00 100.00 96.15 95.83 
%HPV16+ 0.00 0.00 50.00 58.82 59.62 58.33 
%HSIL+ Cytology‡ 0.00  0.00  100.00  75.0  82.76 79.55 
 
Total 
N 1147 811 898 1087 54 3997 
 
%cell 28.70 20.29 22.47 27.20 1.35 10.00 
%p16 IHC+ 17.44 57.58 83.30 96.04 96.30 62.82 
%HPV16+ 9.24 18.99 40.98 56.58 59.26 31.90 
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  %HSIL+ Cytology‡ 12.08 13.15 23.46 41.61 80.00 23.61 
 ptrend (p16) = <.001 <.001 <.001 <.001 .78 <.001 
 ptrend (HPV16) = <.001 <.001 <.001 <.001 .79 <.001 
 ptrend (HSIL+ Cytology) = <.001 <.001 <.001 <.001 .046 <.001 
13 cases excluded as diagnosed as adenocarcinoma in situ or adenocarcinoma by EP (3 CP CIN1, 3 CP CIN2, 6 CP CIN3 and 1 CP SCC)  
*68 Missing Cytology (63 EP negative, 5 EP CIN1)  
**108 Missing Cytology (63 EP negative, 41 EP CIN1, 3 EP CIN2, 1 EP CIN3) 
§152 Missing Cytology (34 EP negative, 46 EP CIN1, 47 EP CIN2, 25 EP CIN3) 
†155 Missing Cytology (10 EP negative, 4 EP CIN1, 38 EP CIN2, 102 EP CIN3, 1 EP SCC) 
‡28 Missing Cytology (5 EP CIN3, 23 EP SCC [squamous cell carcinoma])  
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Table 3. The relationships of community pathology-diagnosed CIN3 and CIN2, stratified on p16 IHC result, with biomarkers of cervical cancer risk: 
the biopsy testing positive for human papillomavirus type 16 (HPV16), an antecedent high-grade intraepithelial lesion (HSIL) or more severe 
(HSIL+) cytologic interpretation, and an expert panel review histopathological diagnosis of cervical intraepithelial neoplasia (CIN) grade 3 (CIN3) or 
more severe (CIN3+) or CIN grade 2 (CIN2) or more severe (CIN2+). Below the individual biomarker results, the relationships of the diagnoses with 
combinations of any (or) or all (and) biomarkers are shown. 
 p16 IHC-
Negative CIN2 
p16 IHC-
Positive CIN2 CIN3 p† ptrend‡ 
Biomarker Result N % N % N % 
HPV16 Positive 91 21.41 415 38.18 658 54.47 <.001 <.001 
HSIL+ Cytology* 80 21.11 206 21.02 447 42.53 <.001 <.001 
EP Diagnosis of CIN3+ 22 5.18 249 22.91 789 65.31 <.001 <.001 
EP Diagnosis of CIN2+ 118 27.76 700 64.40 1,064 88.08 <.001 <.001 
HPV16 Positive, HSIL+, and/or EP Diagnosis of CIN3+ 163 38.35 633 58.23 1,038 85.93 <.001 <.001 
HPV16 Positive, HSIL+, and EP Diagnosis of CIN3+ 3 0.71 27 2.48 192 15.89 <.001 <.001 
*46 p16 IHC-Negative CIN2, 107 p16 IHC-Positive CIN2 and 157 CIN3 missing antecedent cytology 
†p16 IHC-positive CIN2 vs. CIN3 
‡trend for p16 IHC-negative CIN2 vs. p16 IHC-positive CIN2 vs. CIN3  
31 
 
Table 4. The relationships of community pathology (CP)-diagnosed cervical intraepithelial neoplasia grade 2 (CIN2), stratified by p16 
immunohistochemistry (IHC) results and antecedent cytologic interpretation categorized as high-grade squamous intraepithelial lesion (HSIL) or 
more severe (HSIL+) vs. not (<HSIL), with human papillomavirus (HPV) categories and compared to CP-diagnosed CIN3. One hundred fifty-three 
cases were missing antecedent cytology results. “%Col” is the column percentage i.e., the number in cell divide by the total column number. 
 Community Pathology-Diagnosed CIN2 
 p16 IHC  
Negative 
p16 IHC  
Negative 
p16 IHC  
Positive 
p16 IHC  
Positive 
 <HSIL Cytology HSIL+ Cytology <HSIL Cytology HSIL+ Cytology 
HPV Risk Group‡ N %col N %col N %col N %col 
HPV16 61 20.4 18 22.5 284 36.7 88 42.7 
HPV18/45 16 5.4 9 11.3 54 7.0 17 8.3 
Other High Risk* 127 42.5 28 35.0 360 46.5 87 42.2 
Intermediate Risk** 21 7.0 5 6.3 46 5.9 8 3.9 
Low Risk¥ 15 5.0 1 1.3 6 0.8 0 0.0 
HPV Negative 59 19.7 19 23.8 24 3.1 6 2.9 
ptrend (vs. CIN3†) <.001 <.001 <.001 .012 
‡Defined hierarchically according to cancer risk 
*HPV31, 33, 35, 39, 51, 52, 56, 58, 59, and 68 
**HPV26, 53, 66, 67, 70, 73, and 82 
¥HPV6, 11, 40, 42, 54, 55, 61, 62, 64, 69, 71, 72, 81, 82v, 83, 84, and 89 
†Compared to data combining p16 IHC-negative and p16 IHC-positive CIN3 from Table 1  
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Figure 1. Consort diagram of specimen inclusions and exclusions. Abbreviations: CIN, cervical intraepithelial 
neoplasia; CIN2, CIN grade 2; CIN3, CIN grade 3; AIS, adenocarcinoma in situ; ADCA, adenocarcinoma; 
SCC, squamous cell carcinoma; CP, community pathologists; EP, expert pathologists 
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